What does FDA approval of subcutaneous Sarclisa Escena mean for multiple myeloma?

The FDA cleared Sanofi’s isatuximab‑irfc (Sarclisa Escena) as a subcutaneous injection for multiple myeloma, covering relapsed, refractory, and newly diagnosed indications. The on‑body CirCLIQ delivery system offers efficacy comparable to IV Sarclisa while improving convenience, potentially streamlining infusion‑center operations and expanding outpatient use.